key: cord-0982757-wgdh1m9d
authors: Kadono, Yoshinori; Nakamura, Yusaku; Ogawa, Yoshihiko; Yamamoto, Shota; Kajikawa, Ryuichiro; Nakajima, Yoshikazu; Matsumoto, Masayasu; Kishima, Haruhiko
title: A case of COVID-19 infection presenting with a seizure following severe brain edema
date: 2020-06-09
journal: Seizure
DOI: 10.1016/j.seizure.2020.06.015
sha: 806479c51dcccea20825446a2dee8b09033f3389
doc_id: 982757
cord_uid: wgdh1m9d

nan

The novel infection of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 in China and is now widely spread worldwide. COVID-19 commonly presents with respiratory symptoms including cough and dyspnea. However, the neuroinvasive propensity through the angiotensin-converting enzyme 2 (ACE2) receptor [1] , which is expressed in glial cells and neurons as well, and the cerebrovascular complication because of the hypercoagulable state are also reported as a feature of COVID-19 [2] . An immediate neurological care is important to minimize the mortality and morbidity of patients with convulsion and other neurological emergencies. An understanding of potential neurological manifestations in COVID-19 cases is crucial to care for patients and the protection of medical workers appropriately. We report a case of a patient presenting an acute symptomatic seizure with a recurrence of severe brain edema post cerebral venous thrombosis who was later found to have a COVID-19 infection.

J o u r n a l P r e -p r o o f

In April 2020, a 44-year-old man was transferred to our emergency room for an intermittent twitch on the left hand and face. Six months ago, he had symptomatic epilepsy following cerebral venous thrombosis with acute hemorrhagic infarction because of nephrosis. The venous thrombosis was involved the right sphenoparietal sinus and a right front-temporal decompression surgery was performed. After surgery, he was seizure-free with 1500 mg/day levetiracetam for five months. He also received anticoagulation therapy with warfarin (international normalized ratio [INR] range: 2.0-3.0) and a maintenance dose of 20 mg/day prednisone for nephrosis. Before admission, the last INR was 2.3. A week before admission, he felt bulging of a scalp flap. Two days before admission, he noticed the loss of smell. On the morning of the admission day, he had numbness in his left hand and face and called the ambulance. In the ambulance, his oxygen saturation was 97%, and his body temperature was 37.5 °C. Just after arrival, he had a seizure, starting from jerking of his left hand and then the entire body. The focal aware seizure lasted for a few minutes before the administration of 7.5 mg diazepam. A head computed tomography (CT) showed severe brain swelling of the right J o u r n a l P r e -p r o o f temporal lobe, which was injured by the previous hemorrhagic infarction, compared to the last CT ( Fig. 1A and B ). Brain magnetic resonance images did not show any acute cerebral infarction or any new vessel obstruction (Fig. 1D, E, prevented a seizure recurrence. On hospital day 13, a negative report of RT-PCR for SARS-CoV-2 was obtained twice, then he was discharged. At discharge, the D-dimer level was normal, and INR was 4.1. The head CT two weeks after discharge showed improvement in the brain swelling (Fig. 1C ).

COVID-19 is a novel infection that became pandemic but the pathophysiology has been uncertain. Coronaviruses commonly have the pathogenic mechanisms of neuroinvasion through ACE2 receptor [1] , which may be applicable for SARS-CoV-2. This may explain anosmia in COVID-19 [3] . Furthermore, COVID-19 may predispose the patient to a hypercoagulable state. In a study of Italy, although patients received standard J o u r n a l P r e -p r o o f thromboprophylaxis, the cumulative rate of venous thromboembolism was 21% in 388 patients with COVID-19 [2] . Although we lack data on the cerebrospinal fluid of the patient, the anosmia and transient brain edema indicate a neurological invasion of COVID-19. A cerebrovascular event because of the hypercoagulable state of COVID-19 may also cause the recurrence of brain edema. Cerebral angiography and perfusion study were not performed; however, the magnetic resonance results do not show major vessel thrombosis. In this case, microcirculation might be disturbed in COVID-19 infection that could develop edema and lead to the seizure. Although data are lacking to verify the hypothesis, another case of COVID-19 presenting a post-encephalitic status epilepticus [4] and previous reports on the hypercoagulable and neuroinvasive features of COVID-19 support this. However, we believe that COVID-19 infection has a potential to develop brain edema and lead to the seizure in patients with post-stroke symptomatic epilepsy. Thus, we hope that this case report will increase the awareness of neurologists about epilepsy during a COVID-19 infection in emergent medicine and help in providing appropriate care to the patients. 

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Potential pathogenesis of ageusia and anosmia in COVID-19 patients

Focal status epilepticus as unique clinical feature of COVID-19: A case report

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.J o u r n a l P r e -p r o o f